Immune Pharmaceuticals Inc  

(Public, NASDAQ:IMNP)   Watch this stock  
Find more results for IMNP
+0.03 (1.21%)
Jul 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.43 - 2.64
52 week 2.11 - 10.20
Open 2.50
Vol / Avg. 0.00/100,139.00
Mkt cap 25.12M
P/E     -
Div/yield     -
EPS -7.76
Shares 10.09M
Beta 2.61
Inst. own 4%
Jun 15, 2017
Q1 2017 Immune Pharmaceuticals Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -79.25% -118.15%
Return on average equity -479.94% -783.23%
Employees 9 -
CDP Score - -


430 East 29Th Street, Suite 940
NEW YORK, NY 10016
United States - Map
+1-646-4409310 (Phone)
+1-917-3981915 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

Officers and directors

Elliot M. Maza J.D., CPA Interim Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
John Militello CPA Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Controller
Age: 42
Bio & Compensation  - Reuters
Cameron Durrant M.D. Lead Independent Director
Age: 54
Bio & Compensation  - Reuters
Daniel G. Teper Pharm.D. Director
Age: 55
Bio & Compensation  - Reuters
John A Neczesny Independent Director
Bio & Compensation  - Reuters
Jeffrey Paley M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters